Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus ...

Financially, Creative Medical has limited cash reserves, high cash burn, and will likely need dilutive financing. Click here ...

Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Ital ...

Brian Culley; Chief Executive Officer, Director; Lineage Cell Therapeutics Inc Jill Howe; Chief Financial Officer; Lineage Cell Therapeutics Inc William Wood; Analyst; B. Riley Securities Jack Allen; ...

The expansion of patient population and reach is well supported by the ability to produce FT819 in large quantities from a master cell bank, ensuring consistent ... Human induced pluripotent stem ...

Patient dosing underway in CALiPSO-1 trial in the U.S.: In March 2025, the first patient was dosed in the Phase 1 CALiPSO-1 trial which is currently evaluating CNTY-101 as a potential treatment for ...

Stem cell therapy shows early promise for treating Parkinson's. Discover who is in the race to bring this breakthrough to ...

SINGAPORE - Thailand-listed Medeze Group is making a move to acquire a 10 per cent stake in Singapore-listed cord blood bank Cordlife ... east Asia’s largest stem cell storage and services ...

Explore Lineage Cell Therapeutics' Q1 2025 insights, including OpRegen progress, a manufacturing milestone, key clinical data, and a strong financial outlook.

In the realm of medical breakthroughs, Pasona Group Inc.'s Pasona Natureverse pavilion is showcasing a beating heart created from iPS (induced pluripotent stem) cells. Over at the towering Grand ...